Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -2,024.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1,067.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -1,272.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -2,228.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -5,426.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4,612.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -203.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -1.75 Mn |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 7,118.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,118.00 |
| Mar 31, 2026 | 2,942.00 |
| Dec 31, 2025 | 4.12 Mn |
| Sep 30, 2025 | 6,829.00 |
| Jun 30, 2025 | 6,790.00 |
| Mar 31, 2025 | 13,765.00 |
| Dec 31, 2024 | 6,670.00 |
| Sep 30, 2024 | 6,466.00 |
| Jun 30, 2024 | 5,110.00 |
| Mar 31, 2024 | 26,251.00 |
| Dec 31, 2023 | 105,276.00 |
| Sep 30, 2023 | 60,567.00 |
| Jun 30, 2023 | 106,029.00 |
| Mar 31, 2023 | 41,580.00 |
| Dec 31, 2022 | -414.00 |
| Sep 30, 2022 | 151,867.00 |
| Jun 30, 2022 | 165,534.00 |
| Mar 31, 2022 | 30,353.00 |
| Dec 31, 2021 | 81,152.00 |
| Sep 30, 2021 | 235,450.00 |